JP2023531709A5 - - Google Patents

Info

Publication number
JP2023531709A5
JP2023531709A5 JP2022579835A JP2022579835A JP2023531709A5 JP 2023531709 A5 JP2023531709 A5 JP 2023531709A5 JP 2022579835 A JP2022579835 A JP 2022579835A JP 2022579835 A JP2022579835 A JP 2022579835A JP 2023531709 A5 JP2023531709 A5 JP 2023531709A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
isotopolog
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531709A (ja
JP7778095B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038625 external-priority patent/WO2021262812A1/en
Publication of JP2023531709A publication Critical patent/JP2023531709A/ja
Publication of JP2023531709A5 publication Critical patent/JP2023531709A5/ja
Application granted granted Critical
Publication of JP7778095B2 publication Critical patent/JP7778095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579835A 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法 Active JP7778095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2023531709A JP2023531709A (ja) 2023-07-25
JP2023531709A5 true JP2023531709A5 (cg-RX-API-DMAC7.html) 2024-06-18
JP7778095B2 JP7778095B2 (ja) 2025-12-01

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579835A Active JP7778095B2 (ja) 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (9)

Country Link
US (2) US11739075B2 (cg-RX-API-DMAC7.html)
EP (1) EP4171568B1 (cg-RX-API-DMAC7.html)
JP (1) JP7778095B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027213A (cg-RX-API-DMAC7.html)
CN (1) CN115955979B (cg-RX-API-DMAC7.html)
AR (1) AR122725A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048462T3 (cg-RX-API-DMAC7.html)
TW (1) TW202216681A (cg-RX-API-DMAC7.html)
WO (1) WO2021262812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
US20240408085A1 (en) 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
KR20250020448A (ko) 2022-06-02 2025-02-11 시젱 하이스코 파마수티칼 씨오., 엘티디. Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
CN122497677A (zh) 2023-10-20 2026-07-31 奇树医药公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179434A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule ras inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
BR112021011968A2 (pt) 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Similar Documents

Publication Publication Date Title
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2023531495A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2024526191A5 (cg-RX-API-DMAC7.html)
JP2019094345A5 (cg-RX-API-DMAC7.html)
JP2021535207A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
JP2022520448A5 (cg-RX-API-DMAC7.html)
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2019500352A5 (cg-RX-API-DMAC7.html)
JP2021523159A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2015516420A5 (cg-RX-API-DMAC7.html)
JP2018504437A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019537559A5 (cg-RX-API-DMAC7.html)
JP2022514347A5 (cg-RX-API-DMAC7.html)
JP2021528427A5 (cg-RX-API-DMAC7.html)
JP2010527985A5 (cg-RX-API-DMAC7.html)
JP2014514290A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
JP2020063289A5 (cg-RX-API-DMAC7.html)